Bedrocan Expands UK Distribution Partnership with New Partner
Dutch pharmaceutical cannabis producer Bedrocan has announced a new UK distribution partnership, expanding access to its standardised flower products for British patients and prescribers.
Bedrocan, the Netherlands-based pharmaceutical cannabis producer known for its rigorously standardised flower products, has announced a new distribution agreement for the UK market. The partnership will expand the availability of its range to a greater number of licensed UK pharmacies and clinic networks, benefiting patients who rely on consistent, pharmaceutical-grade products.
About Bedrocan Products
Bedrocan is one of the most established pharmaceutical cannabis producers in the world, supplying products that are cultivated and processed under strict pharmaceutical manufacturing standards. The product range includes multiple cultivars with precisely defined THC and CBD profiles, and its consistency is widely valued by clinicians and patients who require reliable dosing.
- Bedrocan at 22% THC, less than 1% CBD, a high THC flower for experienced patients
- Bedrobinol at 13.5% THC, a mid-range THC product
- Bediol at 6.3% THC and 8% CBD, a balanced formulation
- Bedrolite at less than 1% THC and 9% CBD, a CBD-dominant option
Implications for UK Patients
The expanded distribution agreement means that Bedrocan products should be more readily available through a wider range of dispensing partners, reducing wait times and improving supply consistency. Bedrocan's pharmaceutical-grade standards also make its products particularly suitable for patients and clinicians who prioritise regulatory assurance and batch-to-batch consistency in prescribing decisions.
Patients interested in Bedrocan products should discuss availability with their prescribing specialist. You can explore the full range of UK-available strains in our directory. For clinic recommendations and referrals, visit our clinic finder. Our prescription guide helps new patients navigate the system.
